{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T11:29:00Z","timestamp":1785583740644,"version":"3.56.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Natural Science Foundation of Jiangxi Province","award":["20242BAB26146"],"award-info":[{"award-number":["20242BAB26146"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82160464"],"award-info":[{"award-number":["82160464"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the \u201cDouble Thousand\u201d project for training high-level talents of scientific and technological innovation in Jiangxi Province","award":["jxsq2023201038"],"award-info":[{"award-number":["jxsq2023201038"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-026-04816-3","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:06:09Z","timestamp":1776917169000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immune checkpoint inhibitor resistance in dMMR high-grade intraepithelial neoplasia with lynch syndrome-associated colon cancer: a case report"],"prefix":"10.1186","volume":"26","author":[{"given":"Liping","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanjuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbo","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziling","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,23]]},"reference":[{"key":"4816_CR1","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/s41575-019-0189-8","volume":"16","author":"N Keum","year":"2019","unstructured":"Keum N, Giovannucci E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol. 2019;16:713\u201332.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"4816_CR2","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S2468-1253(21)00426-X","volume":"7","author":"SG Patel","year":"2022","unstructured":"Patel SG, Karlitz JJ, Yen T, Lieu CH, Boland CR. The rising tide of early-onset colorectal cancer: a comprehensive review of epidemiology, clinical features, biology, risk factors, prevention, and early detection. Lancet Gastroenterol Hepatol. 2022;7:262\u201374.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4816_CR3","first-page":"394","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"4816_CR4","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0029","volume":"22","author":"AB Benson","year":"2024","unstructured":"Benson AB, Venook AP, Adam M, Chang G, Chen YJ, Ciombor KK, et al. Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024;22:e240029.","journal-title":"J Natl Compr Canc Netw"},{"key":"4816_CR5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","volume":"34","author":"A Cervantes","year":"2023","unstructured":"Cervantes A, Adam R, Rosell\u00f3 S, Arnold D, Normanno N, Ta\u00efeb J, et al. Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:10\u201332.","journal-title":"Ann Oncol"},{"key":"4816_CR6","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9 T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383:2207\u201318.","journal-title":"N Engl J Med"},{"key":"4816_CR7","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0140-6736(24)02848-4","volume":"405","author":"T Andr\u00e9","year":"2025","unstructured":"Andr\u00e9 T, Elez E, Lenz HJ, Jensen LH, Touchefeu Y, Van Cutsem E, et al. Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial. Lancet. 2025;405:383\u201395.","journal-title":"Lancet"},{"key":"4816_CR8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cmet.2019.06.001","volume":"30","author":"I Vitale","year":"2019","unstructured":"Vitale I, Manic G, Coussens LM, Kroemer G, Galluzzi L. Macrophages and metabolism in the tumor microenvironment. Cell Metab. 2019;30:36\u201350.","journal-title":"Cell Metab"},{"key":"4816_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107753","volume":"221","author":"Y Xiao","year":"2021","unstructured":"Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther. 2021;221:107753.","journal-title":"Pharmacol Ther"},{"key":"4816_CR10","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24:541\u201350.","journal-title":"Nat Med"},{"key":"4816_CR11","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1007\/s00262-021-03076-2","volume":"71","author":"JN Guo","year":"2022","unstructured":"Guo JN, Chen D, Deng SH, Huang JR, Song JX, Li XY, et al. Identification and quantification of immune infiltration landscape on therapy and prognosis in left- and right-sided colon cancer. Cancer Immunol Immunother. 2022;71:1313\u201330.","journal-title":"Cancer Immunol Immunother"},{"key":"4816_CR12","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/s41587-021-00994-5","volume":"39","author":"W Xiao","year":"2021","unstructured":"Xiao W, Ren L, Chen Z, Fang LT, Zhao Y, Lack J, et al. Toward best practice in cancer mutation detection with whole-genome and whole-exome sequencing. Nat Biotechnol. 2021;39:1141\u201350.","journal-title":"Nat Biotechnol"},{"key":"4816_CR13","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1200\/JCO.22.00364","volume":"41","author":"JT Topham","year":"2023","unstructured":"Topham JT, O\u2019Callaghan CJ, Feilotter H, Kennecke HF, Lee YS, Li W, et al. Circulating tumor DNA identifies diverse landscape of acquired resistance to anti-epidermal growth factor receptor therapy in metastatic colorectal cancer. J Clin Oncol. 2023;41:485\u201396.","journal-title":"J Clin Oncol"},{"key":"4816_CR14","doi-asserted-by":"publisher","first-page":"3550","DOI":"10.1158\/1078-0432.CCR-18-0103","volume":"24","author":"RA Toledo","year":"2018","unstructured":"Toledo RA, Garralda E, Mitsi M, Pons T, Monsech J, Vega E, et al. Exome sequencing of plasma DNA portrays the mutation landscape of colorectal cancer and discovers mutated VEGFR2 receptors as modulators of antiangiogenic therapies. Clin Cancer Res. 2018;24:3550\u20139.","journal-title":"Clin Cancer Res"},{"key":"4816_CR15","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1056\/NEJMoa2400634","volume":"390","author":"M Chalabi","year":"2024","unstructured":"Chalabi M, Verschoor YL, Tan PB, Balduzzi S, Van Lent AU, Grootscholten C, et al. Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer. N Engl J Med. 2024;390:1949\u201358.","journal-title":"N Engl J Med"},{"key":"4816_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113253","volume":"192","author":"JH Yu","year":"2023","unstructured":"Yu JH, Xiao BY, Tang JH, Li DD, Wang F, Ding Y, et al. Efficacy of PD-1 inhibitors for colorectal cancer and polyps in Lynch syndrome patients. Eur J Cancer. 2023;192:113253.","journal-title":"Eur J Cancer"},{"key":"4816_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1016646","volume":"13","author":"J Shan","year":"2022","unstructured":"Shan J, Han D, Shen C, Lei Q, Zhang Y. Mechanism and strategies of immunotherapy resistance in colorectal cancer. Front Immunol. 2022;13:1016646.","journal-title":"Front Immunol"},{"key":"4816_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01578-x","volume":"17","author":"X Chong","year":"2024","unstructured":"Chong X, Madeti Y, Cai J, Li W, Cong L, Lu J, et al. Recent developments in immunotherapy for gastrointestinal tract cancers. J Hematol Oncol. 2024;17:65.","journal-title":"J Hematol Oncol"},{"key":"4816_CR19","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41416-019-0599-y","volume":"121","author":"IH Sahin","year":"2019","unstructured":"Sahin IH, Akce M, Alese O, Shaib W, Lesinski GB, El-Rayes B, et al. Immune checkpoint inhibitors for the treatment of MSI-H\/MMR-D colorectal cancer and a perspective on resistance mechanisms. Br J Cancer. 2019;121:809\u201318.","journal-title":"Br J Cancer"},{"key":"4816_CR20","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1158\/2159-8290.CD-17-1327","volume":"8","author":"CS Grasso","year":"2018","unstructured":"Grasso CS, Giannakis M, Wells DK, Hamada T, Mu XJ, Quist M, et al. Genetic mechanisms of immune evasion in colorectal cancer. Cancer Discov. 2018;8:730\u201349.","journal-title":"Cancer Discov"},{"key":"4816_CR21","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.cell.2020.11.041","volume":"184","author":"Y Sun","year":"2021","unstructured":"Sun Y, Wu L, Zhong Y, Zhou K, Hou Y, Wang Z, et al. Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. Cell. 2021;184:404-21.e16.","journal-title":"Cell"},{"key":"4816_CR22","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41586-024-08087-4","volume":"634","author":"CK Mo","year":"2024","unstructured":"Mo CK, Liu J, Chen S, Storrs E, Targino da Costa A, Houston A, et al. Tumour evolution and microenvironment interactions in 2D and 3D space. Nature. 2024;634:1178\u201386.","journal-title":"Nature"},{"key":"4816_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01471-y","volume":"8","author":"L Sun","year":"2023","unstructured":"Sun L, Su Y, Jiao A, Wang X, Zhang B. T cells in health and disease. Signal Transduct Target Ther. 2023;8:235.","journal-title":"Signal Transduct Target Ther"},{"key":"4816_CR24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41591-018-0266-5","volume":"25","author":"W Scheper","year":"2019","unstructured":"Scheper W, Kelderman S, Fanchi LF, Linnemann C, Bendle G, de Rooij M, et al. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. Nat Med. 2019;25:89\u201394.","journal-title":"Nat Med"},{"key":"4816_CR25","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/ni1582","volume":"9","author":"E Vivier","year":"2008","unstructured":"Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 2008;9:503\u201310.","journal-title":"Nat Immunol"},{"key":"4816_CR26","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1053\/j.gastro.2009.10.057","volume":"138","author":"B Mlecnik","year":"2010","unstructured":"Mlecnik B, Tosolini M, Charoentong P, Kirilovsky A, Bindea G, Berger A, et al. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology. 2010;138:1429\u201340.","journal-title":"Gastroenterology"},{"key":"4816_CR27","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.trecan.2021.10.006","volume":"8","author":"P Tall\u00f3n de Lara","year":"2022","unstructured":"Tall\u00f3n de Lara P, Casta\u00f1\u00f3n H, Sterpi M, van den Broek M. Antimetastatic defense by CD8(+) T cells. Trends Cancer. 2022;8:145\u201357.","journal-title":"Trends Cancer"},{"key":"4816_CR28","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1002\/(SICI)1097-0142(19970615)79:12<2320::AID-CNCR5>3.0.CO;2-P","volume":"79","author":"S Coca","year":"1997","unstructured":"Coca S, Perez-Piqueras J, Martinez D, Colmenarejo A, Saez MA, Vallejo C, et al. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer. 1997;79:2320\u20138.","journal-title":"Cancer"},{"key":"4816_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100930","volume":"14","author":"S Nersesian","year":"2021","unstructured":"Nersesian S, Schwartz SL, Grantham SR, MacLean LK, Lee SN, Pugh-Toole M, et al. NK cell infiltration is associated with improved overall survival in solid cancers: a systematic review and meta-analysis. Transl Oncol. 2021;14:100930.","journal-title":"Transl Oncol"},{"key":"4816_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01242","volume":"11","author":"S Zhang","year":"2020","unstructured":"Zhang S, Liu W, Hu B, Wang P, Lv X, Chen S, et al. Prognostic significance of tumor-infiltrating natural killer cells in solid tumors: a systematic review and meta-analysis. Front Immunol. 2020;11:1242.","journal-title":"Front Immunol"},{"key":"4816_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-56441-8","volume":"9","author":"S Edin","year":"2019","unstructured":"Edin S, Kaprio T, Hagstr\u00f6m J, Larsson P, Mustonen H, B\u00f6ckelman C, et al. The prognostic importance of CD20(+) B lymphocytes in colorectal cancer and the relation to other immune cell subsets. Sci Rep. 2019;9:19997.","journal-title":"Sci Rep"},{"key":"4816_CR32","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1002\/ijc.30138","volume":"139","author":"J Berntsson","year":"2016","unstructured":"Berntsson J, Nodin B, Eberhard J, Micke P, Jirstr\u00f6m K. Prognostic impact of tumour-infiltrating B cells and plasma cells in colorectal cancer. Int J Cancer. 2016;139:1129\u201339.","journal-title":"Int J Cancer"},{"key":"4816_CR33","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/imm.13568","volume":"168","author":"J Xia","year":"2023","unstructured":"Xia J, Xie Z, Niu G, Lu Z, Wang Z, Xing Y, et al. Single-cell landscape and clinical outcomes of infiltrating B cells in colorectal cancer. Immunology. 2023;168:135\u201351.","journal-title":"Immunology"},{"key":"4816_CR34","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1111\/jgh.13342","volume":"31","author":"EH van Herk","year":"2016","unstructured":"van Herk EH, Te Velde AA. Treg subsets in inflammatory bowel disease and colorectal carcinoma: characteristics, role, and therapeutic targets. J Gastroenterol Hepatol. 2016;31:1393\u2013404.","journal-title":"J Gastroenterol Hepatol"},{"key":"4816_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071888","volume":"12","author":"JE Olgu\u00edn","year":"2020","unstructured":"Olgu\u00edn JE, Medina-Andrade I, Rodr\u00edguez T, Rodr\u00edguez-Sosa M, Terrazas LI. Relevance of Regulatory T cells during Colorectal Cancer Development. Cancers (Basel). 2020;12:1888.","journal-title":"Cancers (Basel)"},{"key":"4816_CR36","doi-asserted-by":"publisher","first-page":"6121","DOI":"10.4049\/jimmunol.0803646","volume":"182","author":"LW Collison","year":"2009","unstructured":"Collison LW, Pillai MR, Chaturvedi V, Vignali DA. Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35- and IL-10-dependent manner. J Immunol. 2009;182:6121\u20138.","journal-title":"J Immunol"},{"key":"4816_CR37","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1111\/cas.15756","volume":"114","author":"T Watanabe","year":"2023","unstructured":"Watanabe T, Ishino T, Ueda Y, Nagasaki J, Sadahira T, Dansako H, et al. Activated CTLA-4-independent immunosuppression of Treg cells disturbs CTLA-4 blockade-mediated antitumor immunity. Cancer Sci. 2023;114:1859\u201370.","journal-title":"Cancer Sci"},{"key":"4816_CR38","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nm.3909","volume":"21","author":"AJ Gentles","year":"2015","unstructured":"Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21:938\u201345.","journal-title":"Nat Med"},{"key":"4816_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/cmi.2014.83","volume":"12","author":"Y Liu","year":"2015","unstructured":"Liu Y, Cao X. The origin and function of tumor-associated macrophages. Cell Mol Immunol. 2015;12:1\u20134.","journal-title":"Cell Mol Immunol"},{"key":"4816_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0430-2","volume":"10","author":"L Yang","year":"2017","unstructured":"Yang L, Zhang Y. Tumor-associated macrophages: from basic research to clinical application. J Hematol Oncol. 2017;10:58.","journal-title":"J Hematol Oncol"},{"key":"4816_CR41","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","volume":"41","author":"R Noy","year":"2014","unstructured":"Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41:49\u201361.","journal-title":"Immunity"},{"key":"4816_CR42","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.4049\/jimmunol.1700737","volume":"200","author":"SY Nu\u00f1ez","year":"2018","unstructured":"Nu\u00f1ez SY, Ziblat A, Secchiari F, Torres NI, Sierra JM, Raffo Iraolagoitia XL, et al. Human M2 macrophages limit NK cell effector functions through secretion of TGF-\u03b2 and engagement of CD85j. J Immunol. 2018;200:1008\u201315.","journal-title":"J Immunol"},{"key":"4816_CR43","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1189\/jlb.3A1215-552R","volume":"101","author":"T Krneta","year":"2017","unstructured":"Krneta T, Gillgrass A, Poznanski S, Chew M, Lee AJ, Kolb M, et al. M2-polarized and tumor-associated macrophages alter NK cell phenotype and function in a contact-dependent manner. J Leukoc Biol. 2017;101:285\u201395.","journal-title":"J Leukoc Biol"},{"key":"4816_CR44","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/pin.13195","volume":"72","author":"Y Fukuda","year":"2022","unstructured":"Fukuda Y, Tanaka Y, Eto K, Ukai N, Sonobe S, Takahashi H, et al. S100-stained perineural invasion is associated with worse prognosis in stage I\/II colorectal cancer: its possible association with immunosuppression in the tumor. Pathol Int. 2022;72:117\u201327.","journal-title":"Pathol Int"},{"key":"4816_CR45","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/386623a0","volume":"386","author":"C Lengauer","year":"1997","unstructured":"Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature. 1997;386:623\u20137.","journal-title":"Nature"},{"key":"4816_CR46","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/s41575-022-00660-4","volume":"19","author":"K Ray","year":"2022","unstructured":"Ray K. Mapping the malignant transformation from polyps to CRC. Nat Rev Gastroenterol Hepatol. 2022;19:488.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"4816_CR47","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1158\/1078-0432.CCR-18-1942","volume":"25","author":"JJ Luke","year":"2019","unstructured":"Luke JJ, Bao R, Sweis RF, Spranger S, Gajewski TF. WNT\/\u03b2-catenin pathway activation correlates with immune exclusion across human cancers. Clin Cancer Res. 2019;25:3074\u201383.","journal-title":"Clin Cancer Res"},{"key":"4816_CR48","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","volume":"523","author":"S Spranger","year":"2015","unstructured":"Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity. Nature. 2015;523:231\u20135.","journal-title":"Nature"},{"key":"4816_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.108921","volume":"115","author":"J Xue","year":"2019","unstructured":"Xue J, Yu X, Xue L, Ge X, Zhao W, Peng W. Intrinsic \u03b2-catenin signaling suppresses CD8(+) T-cell infiltration in colorectal cancer. Biomed Pharmacother. 2019;115:108921.","journal-title":"Biomed Pharmacother"},{"key":"4816_CR50","doi-asserted-by":"publisher","first-page":"4587","DOI":"10.1158\/1078-0432.CCR-21-0180","volume":"27","author":"JM Loree","year":"2021","unstructured":"Loree JM, Wang Y, Syed MA, Sorokin AV, Coker O, Xiu J, et al. Clinical and functional characterization of atypical KRAS\/NRAS mutations in metastatic colorectal cancer. Clin Cancer Res. 2021;27:4587\u201398.","journal-title":"Clin Cancer Res"},{"key":"4816_CR51","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.7150\/thno.100793","volume":"15","author":"R Li","year":"2025","unstructured":"Li R, He J, Liu C, Jiang Z, Qin J, Liang K, et al. PBRM1 deficiency enhances PD1 immunotherapeutic sensitivity via chromosomal accessibility in colorectal cancer. Theranostics. 2025;15:3316\u201331.","journal-title":"Theranostics"},{"key":"4816_CR52","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.ccell.2020.07.013","volume":"38","author":"V Leko","year":"2020","unstructured":"Leko V, Rosenberg SA. Identifying and targeting human tumor antigens for T cell-based immunotherapy of solid tumors. Cancer Cell. 2020;38:454\u201372.","journal-title":"Cancer Cell"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-04816-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04816-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04816-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T01:02:29Z","timestamp":1780621349000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-04816-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4816"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-04816-3","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,23]]},"assertion":[{"value":"27 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We have obtained written informed consent from the patient for the publication of the case report, and the Medical Ethics Committee of The First Affiliated Hospital of Nanchang University, Nanchang, China, approved the study (IIT\u30102025\u3011Clinical Ethics Approval No. 609).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"346"}}